title: Non-colorectal liver metastases: surgical treatment options.
abstract: OBJECTIVE
  Due to different biological characteristics of non-colorectal liver metastasizes (NCLM), surgical treatment, especially it´s long term results, is a topic of discussion. The aim of the study was to evaluate the single center experience with surgical treatment of NCLM.
  
  
  METHODS
  Seventy two patients were prospectively included. The average length of time after the primary surgery was 3.9 years (0-8.5 years). RFA prevailed -50 patients (69.4%), resection presenting 30.6%. Preoperative chemotherapeutical downstaging or portal vein embolization was performed on 12 patients (16.7%). Resectable or radiofrequency ablation (RFA) treatable extrahepatic metastasizes were removed in 26 patients (36.1%).
  
  
  RESULTS
  One, three and five years patient survival after the liver resection or RFA was 88.6, 72.5 and 36.9%. The best survival rate was in patients with carcinoid (5 years-100%), breast cancer (5 years-33.8%), renal carcinoma (3 years-44.4% ) and gynecological tumors metastasizes (2 years-72.9%). With regards to long-term survival of patients, we did not find any statistically significant difference between RFA and resection. Patients with extrahepatic metastasizes had worse prognosis (p<0.01).
  
  
  CONCLUSIONS
  Liver resection and RFA in NCLM have an unambiguous place in multi-modal curative strategy. The decision for surgical treatment of patients suffering from NCLM, is strictly individual with the aim of achieving qualitative long-term survival.
authors.affiliation: Department of Surgery, School of Medicine, Plxen, Czech Republic. treska@fnplzen.cz
authors.forename: Vladislav
authors.initials: V
authors.lastname: Treska
authors.forename: Vaclav
authors.initials: V
authors.lastname: Liska
authors.forename: Tomas
authors.initials: T
authors.lastname: Skalicky
authors.forename: Alan
authors.initials: A
authors.lastname: Sutnar
authors.forename: Inka
authors.initials: I
authors.lastname: Treskova
authors.forename: Andrea
authors.initials: A
authors.lastname: Narsanska
authors.forename: Monika
authors.initials: M
authors.lastname: Vachtova
mesh_terms: D000328:Adult; D000368:Aged; D017115:Catheter Ablation / Q000009:adverse effects / Q000401:mortality; D017024:Chemotherapy, Adjuvant; D018153:Czech Republic; D004621:Embolization, Therapeutic; D005260:Female; D006498:Hepatectomy / Q000009:adverse effects / Q000401:mortality; D006801:Humans; D008113:Liver Neoplasms / Q000401:mortality / Q000556:secondary* / Q000601:surgery*; D008297:Male; D059146:Metastasectomy / Q000009:adverse effects / Q000401:mortality; D008875:Middle Aged; D020360:Neoadjuvant Therapy; D018579:Patient Selection; D011446:Prospective Studies; D016019:Survival Analysis; D015996:Survival Rate; D017741:Survivors / Q000706:statistics & numerical data; D013997:Time Factors; D016896:Treatment Outcome